David Herron Appointed as Calyx CEO
GLO Healthcare, an expanding healthcare platform formed by CapVest Partners LLP, announces the appointment of David Herron as Calyx Chief Executive Officer (CEO).
Herron brings a wealth of experience to Calyx, having spent more than thirty years building and growing life sciences businesses that provide advanced technology-enabled clinical scientific services to the global biopharma industry.
Prior to joining Calyx, Herron served as President and CEO of Bioclinica (now part of Clario). Under David’s leadership Bioclinica enjoyed a decade of revenue and profit growth, that delivered significant increase in enterprise value that led to the merger with ERT – creating a major player in the industry.
Commenting on the appointment, Renaud Dehareng, Executive Chairman of Calyx said: “We are delighted to welcome David to the Calyx team. He is a leader of the highest caliber with a proven track record of putting momentum behind plans to accelerate corporate growth and development. For Calyx in particular, David’s expertise will enhance the depth, breadth, and quality of services to customers with an ultimate aim to deliver life-saving treatments to patients."
Commenting on his new role, David Herron said: “I am excited to join and lead Calyx, at a time that with new GLO Healthcare investors, there is an inspiring vision in place to accelerate the growth and development of the company. Building on the successes of Calyx to date, my focus will be on ensuring Calyx continues to deliver market-leading scientific knowledge and expertise, combined with excellent service and best in class technology-enabled services.”
Herron’s appointment is effective immediately and he succeeds Renaud Dehareng who has served as interim CEO since the acquisition of Calyx by GLO Healthcare in December 2022. Mr. Dehareng will move to the role of Executive Chairman of Calyx. Kate Briant, Senior Partner at CapVest, will remain a member of the Calyx Board, and as chair of GLO Healthcare.
- ends -
About Calyx and Glo Healthcare
Headquartered in the UK and US, Calyx, is a leading provider of mission-critical software and tech-enabled services to the fast-growing clinical research market. Calyx employs over 1,900 professionals across seven offices in six countries, providing 24/7 services to most of the world's leading bio-pharmaceutical companies. The business is structured around three key specialist areas comprising Medical Imaging (MI), tech-enabled Interactive Response Technology (IRT) and Enterprise Technologies (Clinical Trial Management System, Regulatory Information Management software and Electronic Data Capture software).
Calyx's market-leading service, scientific knowledge and expertise and technology offering, speeds up the delivery of life-saving treatments to millions of patients around the world by accelerating and improving clinical trial outcomes. Its customers include the world's top 20 pharmaceutical companies, and to date, Calyx has supported over 60,000 trials across all clinical phases. Recently, Calyx has committed significant investment to developing its next generation cloud products, significantly strengthening its value proposition and service levels.
Led by CapVest, GLO Healthcare is focused on the development and delivery of superior diagnostic testing and innovative therapies for all major cancers, and other life-threatening diseases.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005533/en/
For more information please contact:
On behalf of GLO Healthcare:
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera2.6.2023 05:00:00 EEST | Press release
With the publication of the final results from the LOW-PV study in the New England Journal of Medicine Evidence conducted by Fondazione per la Ricerca dell'Ospedale di Bergamo (FROM) under the leadership of Professor Tiziano Barbui, AOP Health announces an important advancement reinforcing its clinical development program for ropeginterferon alpha-2b (BESREMi®) in polycythaemia vera (PV), a rare blood cancer. The academic LOW-PV study supported and funded by AOP Health and public organizations in Italy complements a series of trials performed by AOP Health over more than 10 years to achieve marketing authorization in Europe and the Middle East. With these clinical studies, including PEGINVERA, PROUD-PV, and CONTINUATION-PV, AOP Health opened a new area of treatment options for patients suffering from PV. A further study (PEN-PV) was performed to develop a pen for self-injection allowing ease of self-administration, exact dosing and minimal waste of the medical product. AOP Health’s com
The Podium Welcomes the Conquerors of 2023 Taklimakan Rally!2.6.2023 04:33:00 EEST | Press release
Among the 97 autos and 37 motorcycles who have started the Rally in Aksu on May 20, 76 autos and 31 motos have successfully withstood the tough challenges and reached the finish line. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005748/en/ As the 15th edition of Taklimakan Rally, the 2023 Taklimakan Rally lasts for 13 days. The 4258 km total stage contains 1 SSS, 9 stages and 2 rest days. The rally sets foot in the south west of Xinjiang and covers 3 regions of Aksu, Kashgar and Hotan. The multi-terrain stages together with the beautiful scenery has attracted 231 competitors from China and abroad to participate. In the auto category, the final victory goes to Zi Yungang/Wang Zengrong from Shanxi Yunxiang Team. Team BAIC contributes to the podium with Zhang Guoyu/Oriol Mena Valdearcos and Liu Yangui/Chen Feng listed the 2nd and 3rd place. As to the moto, Bradley John Cox and Arunas Gelazninkas continued their good per
UAE’s In-Country Value Projects Driving Billions to Local Firms1.6.2023 19:40:00 EEST | Press release
More than $27.23 billion has been redirected to the local economy since the UAE Ministry of Industry and Advanced Technology (MoIAT) and ADNOC launched major in-country value programs to support domestic industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005886/en/ Sideline of Make It In The Emirates Forum (Photo: AETOSWire) Speaking at the Make in the Emirates Forum today, His Excellency Abdulla Al Shamsi, Assistant Undersecretary of MoIAT, said more than $14.43 billion of investment was redirected to the local economy last year alone, an increase of 25 percent year-on-year. “The National In-Country Value Program is a nationwide program that speaks one language across many different sectors,” HE said. “It’s one methodology and this is something we’re very proud of because it benefits the private sector and when the private sector sees this it helps them prepare, invest, and spend.” The forum heard how the Nati
Carbios and Indorama Ventures Reaffirm Partnership to Build First-of-a-kind PET Biorecycling Plant in France1.6.2023 19:30:00 EEST | Press release
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005872/en/ Carbios and Indorama Ventures reaffirm partnership to build first-of-a-kind PET biorecycling plant in France Carbios (Euronext Growth Paris: ALCRB), a biotech company developing and industrializing biological solutions to reinvent the life cycle of plastic and textiles, and Indorama Ventures Public Company Limited (IVL) (Bloomberg ticker IVL.TB), a global sustainable chemical producer, announce today the signing of a non-binding Memorandum of Understanding (MOU) to form a Joint Venture for the construction of the world’s first PET biorecycling plant in France1. Based on and subject to the comprehensive terms set out in the MOU, Indorama Ventures plans to mobilize about €110 million for the Joint Venture in equity and non-convertible loan financing2, pending final engineering documentation and final economic feasibility studies. Both parties have
PPG opens Color Creation Lab with Chery Automobile in China1.6.2023 16:01:00 EEST | Press release
PPG (NYSE:PPG) today announced the opening of a Color Creation Lab in collaboration with automaker Chery Automobile Co., Ltd. At the facility, located in Wuhu, China, PPG color stylists and Chery designers will create new colors tailored to specific vehicle designs, from initial color recommendations to final materials for application in Chery’s manufacturing plants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005119/en/ Representatives from PPG and Chery Automobile celebrate the opening of a Color Creation Lab in Wuhu, China. (Photo: PPG) “As the leading single-source coatings supplier for automotive manufacturing, PPG is excited to partner with Chery, a company that prioritizes technological innovation and sustainable production,” said Thomas Li, PPG vice president Asia Pacific, Automotive Coatings. “We will leverage our global color leadership to predict future trends, while advancing paint technology for the nex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom